Press
-
Bio-Techne Receives Approval To Offer The ExoDx™ Prostate Intelliscore™ (EPI) Test In New York State
Bio-Techne today announced that it has received a clinical laboratory permit from the New York State Department of Health to provide its ExoDx Prostate IntelliScore (EPI) test in New York, providing a valuable tool to help Urologists rule out unnecessary prostate biopsies. -
ExoDx Prostate(IntelliScore) (EPI) Included in National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection
Bio-Techne Corporation (NASDAQ:TECH) today announced the National Comprehensive Cancer Network (NCCN) decision to include EPI as a recommended test in their Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection (Version 1.2019). -
Bio-Techne To Acquire Exosome Diagnostics, Inc.
-
Exosome Diagnostics Achieves ISO 13485:2016 Certification
-
Exosome Diagnostics Announces Bladder Cancer Surveillance Panel
-
Exosome Diagnostics’ Second Prospective Validation Study of EPI to be Highlighted at American Urological Association (AUA) Annual Meeting Press Briefing in San Francisco, CA
-
Exosome Diagnostics Presents Breakthrough Data Highlighting Tumor Derived RNA in Biofluids at the International Society for Extracellular Vesicles in Spain
-
Exosome Diagnostics Continues to Expand Coverage Reach for its EPI Test
-
Exosome Diagnostics Expands National Sales Team after Blockbuster Quarter with its Flagship Diagnostic, ExoDx Prostate®(IntelliScore) (EPI) Test